Episode 4 - Conversations in Advanced NSCLC: Rationale and Utility of TROP2 Antibody-Drug Conjugates Based on Updates from WCLC and ESMO - Part 1: Rationale for ADCs

This podcast series, lead by expert faculty, inform and guide the safety and efficacy of TROP2-directed ADCs in different settings of NSCLC treatment that was reported at key conferences such as the World Conference on Lung Cancer (WCLC 2023) and European Society of Medical Oncology (ESMO 2023) annual conference. The expert faculty will also discuss insights into using agents upon availability to enable improved outcomes among distinct subsets of patients.

Launch Date: December 29, 2023

Release Date: December 29, 2023

Expiration Date: November 30, 2024

FACULTY BIOS

Benjamin Levy, MD

Associate Professor of Oncology

Johns Hopkins Medicine

Aaron Lisberg, MD

Assistant Professor of Clinical Medicine

University of California, Los Angeles

Alexander Spira, MD, PhD, FACP

Co-Director

Virginia Cancer Specialists Research Institute

This podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode

.https://www.practicepointcme.com/CMEHome/conversations-in-advanced-nsclc-rationale-and-utility-of-trop2-antibody-drug-conjugates-based-on-updates-from-wclc-and-esmo-1